Publication:
Mefloquine concentration profiles during prophylactic dose regimens

dc.contributor.authorHerwig Kollaritschen_US
dc.contributor.authorJuntra Karbwangen_US
dc.contributor.authorGerhard Wiedermannen_US
dc.contributor.authorAndrea Mikolaseken_US
dc.contributor.authorKesara Na-Bangchangen_US
dc.contributor.authorWalter H. Wernsdorferen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversitat Wienen_US
dc.date.accessioned2018-09-07T09:20:34Z
dc.date.available2018-09-07T09:20:34Z
dc.date.issued2000-05-19en_US
dc.description.abstractA pharmacokinetic study with (malaria) prophylactic doses of mefloquine hydrochloride was conducted in 12 healthy adult subjects (Caucasians), 6 females and 6 males, mean age 29.2 ± 6.4 years, mean weight 70.6 ± 13.4 kg. Doses of 250 mg mefloquine were administered on days 0, 1, 7, 14, 21 and 28. Six subjects received a further 5 weekly doses of 250 mg mefloquine, the others 5 further weekly doses of 125 mg. After the third dose the protective threshold mefloquine concentration in blood plasma was achieved in all subjects. In female subjects, mean C(min ss), C(max) ss and AUC(d 0-35) were significantly higher than in males. After the fifth dose, mean Cmax in females reached 1692 ng/ml (4.48 μmol/l), equivalent to a high therapeutic concentration. This is apparently due to a generally lower body weight and a narrower volume of distribution in women. Adverse reactions were significantly more frequent in women than in men. Headache, anorexia, insomnia and vertigo were the most common side effects. The lesser tolerability of mefloquine in females may be due to the higher drug concentrations in this group. This may indicate the need for appropriate adjustment of the prophylactic dose regimen of mefloquine in females.en_US
dc.identifier.citationWiener Klinische Wochenschrift. Vol.112, No.10 (2000), 441-447en_US
dc.identifier.issn00435325en_US
dc.identifier.other2-s2.0-0034685908en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/26243
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0034685908&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleMefloquine concentration profiles during prophylactic dose regimensen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0034685908&origin=inwarden_US

Files

Collections